Cleo Diagnostics (ASX:COV) Total Long-Term Assets: A$0.36 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:COV Cleo Diagnostics Ltd ASX:COV
6 GF Score
Price A$0.36
! 1 Warning Sign
View Full Analysis

What is Cleo Diagnostics Total Long-Term Assets?

Cleo Diagnostics ASX:COV +4.35% 6 Total Long-Term Assets is A$0.36 Mil as of Dec. 2025. GuruFocus rates ASX:COV with a GF Score™ of 6/100. The stock has 1 warning sign investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Cleo Diagnostics's Total Long-Term Assets for the quarter that ended in Dec. 2025 was A$0.36 Mil.

Cleo Diagnostics Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Cleo Diagnostics's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cleo Diagnostics Total Long-Term Assets Chart

Cleo Diagnostics Annual Data
Trend Jun23 Jun24 Jun25
Total Long-Term Assets
0.50 0.85 0.39

Cleo Diagnostics Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Long-Term Assets Get a 7-Day Free Trial 0.47 0.85 0.41 0.39 0.36
ASX:COV
6GF Score
Cleo Diagnostics Ltd ASX:COV
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cleo Diagnostics Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of A$0.36 Mil mean?
Cleo Diagnostics (ASX:COV) has a Total Long-Term Assets of A$0.36 Mil as of Dec. 2025. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Cleo Diagnostics and its competitors.
Is Cleo Diagnostics' Total Long-Term Assets too high?
Cleo Diagnostics' current Total Long-Term Assets is A$0.36 Mil. Overall, Cleo Diagnostics has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Cleo Diagnostics' Total Long-Term Assets compare to ABT and SYK?
Cleo Diagnostics' Total Long-Term Assets of A$0.36 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Medical Devices & Instruments company?
A good Total Long-Term Assets depends on the Medical Devices & Instruments industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Cleo Diagnostics and its competitors. Cleo Diagnostics's current Total Long-Term Assets is A$0.36 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cleo Diagnostics stock overvalued right now?
Cleo Diagnostics (ASX:COV) has a current Total Long-Term Assets of A$0.36 Mil. The current Total Long-Term Assets is A$0.36 Mil. Cleo Diagnostics' overall GF Score™ is 6/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Cleo Diagnostics (ASX:COV), the current Total Long-Term Assets is A$0.36 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cleo Diagnostics Business Description

Address 480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000
Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The company's first product to market is intended to be the Triage Test which results to accurately differentiate patients with malignant ovarian cancer from those with benign gynecological conditions. The company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.
6GF Score

Get the complete analysis for ASX:COV

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.36
Price